Cannabics Pharmaceuticals Establishes a Human-Cannabis-Cancer Genetics lab to Expand its Personalized Diagnostics

TEL AVIV, Israel, July 24, 2017, CNBX, /PRNewswire/ Cannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today announced it has established a Genetic lab that will develop diagnostic tools based on human genome, tumor genetics and cannabinoids. The company recruited Dr. Moran Grinberg to serve as its VP of R&D and to lead the Genetic research. Moran has a PhD in Virology and MSc in clinical pharmacology with vast experience in conceptualizing and executing pharmacological research. Dr. Eyal Ballan, Co-founder and CTO, said: Our mission is to commercialize
http://bit.ly/2tUp12t